DEBORAH DRUMM: Open Payments
NPI 1720192297 · NEWTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,031 in 54 payments from 11 companies in 2025. Trend: 2023 $1,188 · 2024 $1,570 · 2025 $1,031
Food & beverage: $1,031
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $234 |
| ABBVIE INC. | 20 | $187 |
| E.R. Squibb & Sons, L.L.C. | 2 | $140 |
| Neurocrine BioSciences, Inc. | 6 | $111 |
| Lundbeck LLC | 5 | $92 |
| Alkermes, Inc. | 4 | $71 |
| Axsome Therapeutics, Inc. | 4 | $62 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $59 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
Products named: REXULTI, VRAYLAR, COBENFY, INGREZZA, ARISTADA, ABILIFY MAINTENA, CAPLYTA, Sunosi.
Industry payments across NJ — which companies pay providers there.
